"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease "

drug protocol number
CNTO1959CRD3001
drug sponsor
Janssen-Cilag International NV
drug study
Guselkumab
drug trial site
KAMC
drug status
Ongoing
drug phase